Search

Cookies

We use cookies to improve your experience. By continuing, you accept our use of cookies.

Business

Hyderabad Doctor Slashes Rare Disease Drug Cost from ₹9 Cr to ₹2.5 Lakh for Children

· · 3 min read

A Hyderabad pediatrician, Dr. Sivaranjani Santosh, spearheaded an initiative to reduce the annual cost of a life-saving drug for Allan-Herndon-Dudley syndrome (AHDS) from ₹9 crore to ₹2.5 lakh per child. This effort, sparked by a mother's plea, ensures seven Indian children receive the medication free of charge.

An extraordinary cross-border medical effort, ignited by a mother's desperate plea, has dramatically cut the annual cost of a critical rare disease drug for Indian children from as much as ₹9 crore to just ₹2.5 lakh. The initiative, led by Hyderabad-based paediatrician Dr. Sivaranjani Santosh alongside Access to Medicines India, ensures seven children diagnosed with Allan-Herndon-Dudley syndrome (AHDS) will receive a full year's supply of the drug tiratricol completely free.

Understanding Allan-Herndon-Dudley Syndrome (AHDS)

AHDS, also known as MCT8 deficiency, is a rare genetic disorder caused by a defect in the MCT8 thyroid hormone transporter. This defect prevents crucial thyroid hormone from entering brain cells during early development, while simultaneously allowing an excess of triiodothyronine (T3) to flood the rest of the body. Without treatment, children face severe developmental delays, intellectual disability, low muscle tone, uncoordinated movements, a racing heart, and eventual cardio-respiratory failure.

Tiratricol, also known as TRIAC, acts as a mimic of the thyroid hormone, bypassing the defective transporter to protect the brain from damage. In commercial markets like the United States, the branded version of tiratricol (Emcitate) carries an exorbitant price tag, making annual treatment financially prohibitive for most families.

A Mother's Plea Sparks Action

The catalyst for this monumental change was Pavitra, the mother of a young patient named Aarav. She struggled to afford the ₹12-13 lakh monthly cost of importing the medication from Germany. Her outreach via social media—an Instagram direct message and a WhatsApp text—to Dr. Sivaranjani Santosh set the wheels in motion. Dr. Santosh, collaborating with KM Gopakumar of Access to Medicines India, launched a public advocacy campaign to find a sustainable and affordable alternative.

Compounding Breakthrough and Cross-Border Coordination

Initial attempts to secure support from commercial manufacturer Egetis Therapeutics proved unsuccessful. This setback prompted the team to explore pharmaceutical compounding. With crucial backing from the Netherlands-based Pharmaceutical Accountability Foundation (PAF), the Transvaal Pharmacy in The Hague successfully formulated the active pharmaceutical ingredient. This breakthrough brought the average annual cost down to approximately ₹2.5 lakh per child.

Crowdfunding efforts by PAF, combined with generous donations from the parents of Dr. Santosh's own patients, covered all expenses, ensuring the seven families would not pay a single rupee for the medication.

Navigating Regulatory Hurdles

Bringing the compounded medicine to India required meticulous coordination and adherence to strict regulatory channels:

  • Patient Identification: Beyond Aarav and another child in Hyderabad, five additional patients were identified through Dr. Praveen and specialists at Christian Medical College (CMC) in Vellore. A seventh child joined the cohort following a public appeal.
  • Regulatory Clearance: The Organization for Rare Diseases India (ORDI) played a vital role, assisting families in securing individual import permits. Aarav's mother, Pavitra, became an active team member, guiding other parents through the necessary paperwork.
  • Delivery Logistics: Due to tiratricol's six-month shelf life, the one-year supply is being delivered in two batches, with initial handovers scheduled in Hyderabad and Bengaluru.

Call for Domestic Production

While the imported batches offer immediate relief, Dr. Sivaranjani Santosh emphasizes that relying on foreign pharmacies is not a long-term solution. She has made an urgent appeal to the Union government to localize production of the active pharmaceutical ingredient within India. “We can easily prepare it here, and it would cost even less,” she stated on X, advocating for its inclusion under the National Rare Diseases Policy.

She also urged paediatricians, endocrinologists, and neurologists nationwide to share details of children with confirmed or suspected MCT8 deficiency to facilitate diagnosis, treatment, and access to tiratricol.

Related